IMMU Profile
Immunomedics,
Inc. (IMMU) is a biopharmaceutical company that develops monoclonal
antibody-based products for the targeted treatment of cancer and other
serious diseases. The company's lead product candidate, sacituzumab
govitecan (IMMU-132), is currently in clinical development for the
treatment of multiple types of cancer, including metastatic breast
cancer, lung cancer, and bladder cancer.
In December 2020,
Immunomedics was acquired by Gilead Sciences in a deal worth $21
billion. The acquisition was driven by Gilead's interest in expanding
its oncology portfolio with the addition of sacituzumab govitecan,
which has shown promising results in clinical trials.
Prior to
the acquisition, Immunomedics had a strong pipeline of product
candidates in various stages of development, including IMMU-140, which
targets solid tumors, and IMMU-114, which is being developed for the
treatment of non-Hodgkin lymphoma.
Immunomedics has also
entered into collaborations with other biopharmaceutical companies,
such as AstraZeneca, for the development and commercialization of its
product candidates.
Overall, Immunomedics' focus on developing
targeted cancer treatments and its acquisition by Gilead Sciences
demonstrate the company's potential to make significant contributions
to the biopharmaceutica
|
